TY  - JOUR
AU  - Yang, James C.H.
AU  - López-Ríos Moreno, Fernando
AU  - Trent, Jonathan
PY  - 2022
DO  - 10.1186/S12885-022-09687-X
SN  - 1471-2407
UR  - https://hdl.handle.net/20.500.14352/118212
T2  - BMC Cancer
AB  - Background: Tropomyosin receptor kinase (TRK) fusion proteins resulting from neurotrophic tyrosine receptor kinase (NTRK) gene fusions are rare primary oncogenic drivers in a wide array of tumors. Larotrectinib is a first-in-class, highly selective,...
LA  - eng
PB  - BioMed Central
KW  - Larotrectinib
KW  - NTRK gene fusions
KW  - Non-interventional study
KW  - TRK fusion
TI  - Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinib
TY  - journal article
VL  - 22
ER  -